학술논문

BELIMUMAB FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS: A PHASE 2/3, RANDOMISED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL.
Document Type
Article
Source
Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p1668-1668, 1p
Subject
Language
ISSN
00034967